India Is the World's Pharmacy - But Three Risks Could Change That
India supplies approximately 20 percent of the world's generic medicines by volume and is the largest provider of vaccines globally. That position has been built over decades of manufacturing scale, cost efficiency and the development of a strong regulatory compliance culture following several years of intense US FDA scrutiny. A new report from Grant Thornton and FICCI, released on October 5, 2026, identifies the next set of challenges that could test whether that position is sustainable.
Quick Answer: What does the Grant Thornton-FICCI pharma report say about India in 2026? The report identifies data integrity, supply-chain resilience and digital capability as the three areas that will determine whether India maintains its position as a global pharmaceutical leader. Each represents a risk where the gap between current performance and global expectations is widening.
The First Challenge: Data Integrity
The Grant Thornton-FICCI report flags data integrity, supply-chain resilience and digital capability as the next tests for India's global pharma ambitions. Data integrity refers to the accuracy, completeness and consistency of the records that pharmaceutical manufacturers generate and maintain - batch manufacturing records, quality control results, stability data and clinical trial information.
The US FDA and other major regulatory agencies have issued significant numbers of import alerts and warning letters to Indian pharma facilities over the past decade based on data integrity failures. These range from backdated entries in laboratory notebooks to deletion of failed test results. The problem is not universal across India's pharmaceutical industry - some companies have exemplary records - but it has been persistent enough to shape how regulators worldwide view Indian pharma as a category.
Fixing data integrity is as much a cultural challenge as a technical one. It requires that laboratory staff and managers accept that a failed test, documented accurately, is preferable to a manipulated result. Building that culture at scale across India's thousands of pharma manufacturing sites is the work of years, not months.
The Second Challenge: Supply-Chain Resilience
India's pharmaceutical supply chain has two significant structural vulnerabilities. The first is its dependence on China for Active Pharmaceutical Ingredients (APIs) - the chemical building blocks of finished medicines. Estimates suggest India imports 60-70 percent of its API requirements from China, a dependence that became visible during the early COVID-19 pandemic when Chinese factory closures caused API shortages globally.
The government has invested in a Production-Linked Incentive scheme for domestic API manufacturing, and some diversification has occurred. But the underlying dependence has not been fundamentally resolved. A geopolitical disruption, a Chinese export restriction or an environmental crackdown on API manufacturing in China creates a supply chain risk that ripples through to Indian medicine exports.
The second vulnerability is concentration - too many facilities producing the same molecules for the same markets. Diversifying product mix and market destination has been a stated priority for several years; the report suggests the pace of that diversification remains too slow.
The Third Challenge: Digital Capability
Pharmaceutical manufacturing is moving toward continuous manufacturing, process analytical technology and AI-assisted quality systems. Major innovator companies and some contract manufacturers in the US, Europe and Japan are ahead of most Indian generics manufacturers in deploying these technologies at scale. The gap in digital manufacturing capability matters because it affects both production costs and the ability to meet regulatory expectations that are moving toward data-rich, real-time quality assurance.
Indian companies have invested in enterprise software and some automation, but the transition to digitally native manufacturing at a facility level has been slower than the pace of regulatory expectation. The report's point is not that Indian pharma is technologically backward but that the pace of digital transformation needs to accelerate to maintain its competitive position.
India's Pharma in Numbers
| Metric | Figure |
|---|---|
| Share of global generic medicine supply (volume) | ~20% |
| Pharmaceutical export value (FY2026) | ~$30 billion |
| US FDA-approved manufacturing sites in India | Over 700 |
| API import dependence on China | ~60-70% |
| Number of pharma companies in India | Over 3,000 |
Key Takeaways
- Grant Thornton-FICCI October 2026 report identifies data integrity, supply-chain resilience and digital capability as the key risks for India's global pharma position.
- Data integrity failures with major regulators, particularly the US FDA, have been a persistent problem across multiple Indian manufacturers.
- API import dependence on China of 60-70 percent represents a strategic supply chain vulnerability.
- Digital manufacturing transformation is proceeding more slowly than the pace of regulatory expectations from major markets.
Frequently Asked Questions
What is data integrity in pharmaceutical manufacturing?
Data integrity means that all records generated during drug manufacturing are accurate, complete, consistent and traceable. It covers laboratory notebooks, instrument logs, batch records, quality control results and stability data. Regulators treat data integrity failures very seriously because unreliable records undermine the ability to verify that a medicine meets its quality specifications.
How dependent is India's pharma industry on China for APIs?
An estimated 60-70 percent of India's Active Pharmaceutical Ingredient requirements are imported from China. The government's PLI scheme for domestic API production has had some success, but the structural dependence has not been fundamentally reduced.
What is India's pharma export value?
India's pharmaceutical exports were approximately $30 billion in FY2026, making it one of the country's top export earners. The US market takes the largest share, followed by Europe and other regulated markets.
Conclusion
The Grant Thornton-FICCI report is not a verdict against Indian pharma. It is a calibrated assessment of where the next competitive pressure points are. Indian pharmaceutical companies have resolved harder problems before - the early 2000s FDA scrutiny wave that forced an industry-wide compliance overhaul produced companies that are now among the most competent generic manufacturers in the world. The three challenges flagged for 2026 and beyond are addressable. The question the report is really asking is whether they will be addressed at the pace the market and regulators require - or at the pace Indian pharma has historically managed, which has been faster than critics predicted and slower than it could have been.
